Format

Send to

Choose Destination
Future Oncol. 2017 Aug;13(20):1755-1766. doi: 10.2217/fon-2017-0170. Epub 2017 Jun 7.

A review of binimetinib for the treatment of mutant cutaneous melanoma.

Author information

1
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
2
Department of Dermatology, Paracelsus Medical University, Salzburg, Austria.

Abstract

Although significant progress has been made in the treatment of unresectable or metastatic melanoma, at least half of all advanced melanoma patients eventually progress and pass away due to their disease. In particular, patients with NRAS-mutated melanoma still face limited therapeutic options, with immunotherapy being the current treatment type of choice. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. The results of a recent Phase III trial rendered binimetinib the first targeted therapy agent to significantly improve progression-free survival in NRAS-mutated melanoma. This review will summarize the development and clinical data of binimetinib in melanoma in general and also explore the potential future role of this substance as single agent or combination therapy.

KEYWORDS:

BRAF-mutated melanoma; MAPK pathway; NRAS mutations; binimetinib

PMID:
28587477
DOI:
10.2217/fon-2017-0170
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center